
    
      Our primary hypothesis is that autologous bone marrow mononuclear cell transplantation by
      intravenous administration is feasible and safe after acute ischemic stroke. Our secondary
      hypothesis is that autologous transplantation is associated with improved outcome after acute
      stroke.
    
  